Play all audios:
Access through your institution Buy or subscribe The aldosterone antagonist eplerenone is underused in patients with chronic heart failure and reduced ejection fraction, possibly owing to
concerns of hyperkalaemia and worsening renal function in high-risk patients. However, Eschalier _ et al_. found that use of eplerenone was effective in reducing hospitalization for heart
failure and cardiovascular mortality in high-risk patients, and that the risks of potassium levels exceeding 6.0 mmol/l and of hospitalization for hyperkalaemia were not increased (although
the risk of potassium >5.5 mmol/l was increased). This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this
journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now
Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer
support ORIGINAL RESEARCH PAPER * Eschalier, R. _ et al_. Safety and efficacy of eplerenone in patients at high-risk for hyperkalemia and/or worsening renal function: analyses of EMPHASIS-HF
study subgroups. _J. Am. Coll. Cardiol._ doi:10.1016/j.jacc.2013.04.086 Download references RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE
Investigating eplerenone use in high-risk patients. _Nat Rev Nephrol_ 9, 492 (2013). https://doi.org/10.1038/nrneph.2013.134 Download citation * Published: 06 August 2013 * Issue Date:
September 2013 * DOI: https://doi.org/10.1038/nrneph.2013.134 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a
shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative